Swetha Kambhampati, MD
Physician
Publications
Kambhampati S, Herrera AF, Rhee JW. How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations. JACC. CardioOncology 2023. PMID: 37397077
Kambhampati S, Shumilov E, Saumoy M, Herrera AF, Tilly H, Lenz G, Thiruvengadam NR. Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany. British journal of haematology 2023. PMID: 37188351
Ladbury C, Dandapani S, Hao C, Fabros M, Amini A, Sampath S, Glaser S, Sokolov K, Yeh J, Baird JH, Kambhampati S, Herrera A, Mei M, Nikolaenko L, Shouse G, Budde LE. Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma. Cancers 2023. PMID: 36980632
Torka P, Kambhampati S, Chen L, Wang X, Chen C, Vuong D, Qin H, Muir A, Orand K, Borja I, Lynne Smith D, Herrera AF, Spurgeon SEF, Park B, Lewis LD, Hernandez-Ilizaliturri F, Xia Z, Danilov AV. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood cancer journal 2023. PMID: 36631449
Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde LE, Mei MG, Siddiqi T, Popplewell L, Wen YP, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam N. Cost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma. Blood 2022. PMID: 35700381
Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, Mei MG, Popplewell LL, Siddiqi T, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood 2022. PMID: 35914220
Kambhampati S, Zain J. Circulating Tumor DNA in Lymphoma. Current hematologic malignancy reports 2022. PMID: 36214943
Kambhampati S, Mei MG, Godfrey J, Siddiqi T, Salhotra A, Chen R, Smith E, Popplewell LL, Herrera AF. PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia 2022. PMID: 35778267
Kambhampati S, Sheng Y, Huang CY, Bylsma SA, Lo M, Kennedy VE, Natsuhara K, Martin T, Wolf JL, Shah N, Wong SW. Infectious complications in relapsed refractory multiple myeloma patients after BCMA Car t-cell therapy. Blood advances 2021. PMID: 34543400
Ladbury C, Kambhampati S, Othman T, Hao C, Chen L, Wong J, Cao T, Herrera A, Mei M, Dandapani S. Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post Autologous Stem Cell Transplant. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2022. PMID: 35176414
Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf JL, Martin TG, Shah N, Wong SW. Macrophage Activation Syndrome-Like Manifestations (MAS-L) Following BCMA-directed CAR T-cells in Multiple Myeloma. Blood advances 2021. PMID: 34644387
Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kennedy VE, Arora S, Wolf JL, Martin TG, Wong SW, Shah N. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplantation and cellular therapy 2021. PMID: 33831353
Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clinical lymphoma, myeloma & leukemia 2020. PMID: 33478921
Parks AL, Kambhampati S, Fakhri B, Andreadis C, Gray L, Wong SW, Shah N, Fang MC. Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma. Leukemia & lymphoma 2020. PMID: 33258699
Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clinical lymphoma, myeloma & leukemia 2020. PMID: 33288485
Kambhampati S, Tieu AH, Luber B, Wang H, Meltzer SJ. Risk Factors for Progression of Barrett's Esophagus to High Grade Dysplasia and Esophageal Adenocarcinoma. Scientific Reports 2020. PMID: 32184470
Kambhampati S, Galligan D, Huang CY, Wong S, Wolf J, Martin T, Shah N. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. Leukemia & lymphoma 2020. PMID: 31928108
Kambhampati S, Wiita AP. Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer. Advances in experimental medicine and biology 2020. PMID: 32297217
Kambhampati S, Gray L, Fakhri B, Lo M, Vu K, Arora S, Kaplan L, Ai WZ, Andreadis C. Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series. Clinical lymphoma, myeloma & leukemia 2019. PMID: 31948859
Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer 2019. PMID: 31154669
Orimoloye OA, Kambhampati S, Hicks AJ, Al Rifai M, Silverman MG, Whelton S, Qureshi W, Ehrman JK, Keteyian SJ, Brawner CA, Dardari Z, Al-Mallah MH, Blaha MJ. Higher cardiorespiratory fitness predicts long-term survival in patients with heart failure and preserved ejection fraction: the Henry Ford Exercise Testing (FIT) Project. Archives of medical science : AMS 2019. PMID: 30899287
Wang Z, Kambhampati S, Cheng Y, Ma K, Simsek C, Tieu AH, Abraham JM, Liu X, Prasath V, Duncan M, Stark A, Trick A, Tsai HL, Wang H, He Y, Khashab MA, Ngamruengphong S, Shin EJ, Wang TH, Meltzer SJ. Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study. Clinical cancer research : an official journal of the American Association for Cancer Research 2019. PMID: 30670490
Hsu S, Kambhampati S, Sciortino CM, Russell SD, Schulman SP. Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock. American heart journal 2017. PMID: 29754660
Moran RA, Jalaly NY, Kamal A, Rao S, Klapheke R, James TW, Kambhampati S, Makary MA, Hirose K, Kumbhari V, Stein EM, Khashab MA, Lennon AM, Kalloo AN, Zaheer A, Hernaez R, Singh VK. Ileus is a predictor of local infection in patients with acute necrotizing pancreatitis. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2016. PMID: 27727097
Kambhampati S, Ashvetiya T, Stone NJ, Blumenthal RS, Martin SS. Shared Decision-Making and Patient Empowerment in Preventive Cardiology. Current cardiology reports 2016. PMID: 27098670
Rizal RE, Mediratta RP, Xie J, Kambhampati S, Hills-Evans K, Montacute T, Zhang M, Zaw C, He J, Sanchez M, Pischel L. Galvanizing medical students in the administration of influenza vaccines: the Stanford Flu Crew. Advances in medical education and practice 2015. PMID: 26170731
Kambhampati S, Park W, Habtezion A. Pharmacologic therapy for acute pancreatitis. World journal of gastroenterology 2014. PMID: 25493000
Ghebremariam YT, Huang NF, Kambhampati S, Volz KS, Joshi GG, Anslyn EV, Cooke JP. Characterization of a fluorescent probe for imaging nitric oxide. Journal of vascular research 2013. PMID: 24335468
Kastrup CJ, Nahrendorf M, Figueiredo JL, Lee H, Kambhampati S, Lee T, Cho SW, Gorbatov R, Iwamoto Y, Dang TT, Dutta P, Yeon JH, Cheng H, Pritchard CD, Vegas AJ, Siegel CD, MacDougall S, Okonkwo M, Thai A, Stone JR, Coury AJ, Weissleder R, Langer R, Anderson DG. Painting blood vessels and atherosclerotic plaques with an adhesive drug depot. Proceedings of the National Academy of Sciences of the United States of America 2012. PMID: 23236189